Peptides

Tesamorelin: FDA-Approved GH Peptide — Dosage, Benefits, and Uses

The only FDA-approved GHRH analog for visceral fat reduction — and what that means for off-label use

Tesamorelin (Egrifta) is an FDA-approved GHRH analog with the strongest clinical evidence base of any growth hormone peptide. Originally approved for HIV-associated lipodystrophy, it's increasingly used off-label for visceral fat reduction and GH optimization.

Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone that was FDA-approved in 2010 for HIV-associated lipodystrophy — a condition where antiretroviral medications cause problematic visceral fat accumulation. It has the most robust clinical evidence base of any GHRH peptide, with multiple Phase III randomized controlled trials in humans.

Tesamorelin reduces visceral adipose tissue significantly more than any other GHRH-class peptide in head-to-head clinical comparisons. While its FDA approval is narrow (HIV lipodystrophy), it's increasingly used off-label in anti-aging and functional medicine for visceral fat reduction and growth hormone optimization.

Tesamorelin Clinical Evidence

Key clinical findings from FDA-registration trials and post-market research:

Tesamorelin Dosage

FDA-approved dosing (HIV lipodystrophy) and off-label protocols:

Tesamorelin vs Sermorelin: Key Differences

FactorTesamorelinSermorelin
Half-life~26 minutes~12 minutes
FDA statusApproved (HIV lipodystrophy)Approved (GH deficiency, children)
Clinical evidenceMultiple Phase III RCTsDecades of off-label clinical use
Visceral fat reductionSuperior (primary endpoint in trials)Present but less studied
CostVery high (brand: $3,000–5,000/mo)$150–400/mo (compounded)
Typical useDaily standaloneDaily, often stacked with GHRP

Frequently Asked Questions

What is tesamorelin?

Tesamorelin (Egrifta) is an FDA-approved synthetic GHRH analog used clinically for HIV-associated lipodystrophy. It stimulates pituitary GH release and is particularly effective at reducing visceral adipose tissue — the dangerous fat around organs linked to cardiovascular disease and metabolic syndrome. It has the strongest clinical evidence base of any GHRH peptide.

What is the tesamorelin dosage?

The FDA-approved dose for HIV lipodystrophy is 2 mg subcutaneously daily. Off-label anti-aging protocols typically use 1–2 mg daily. Monitoring IGF-1 at 3 months is recommended to ensure levels are in the age-appropriate optimal range without exceeding safe limits.

Tesamorelin vs sermorelin — which is better?

Tesamorelin has stronger clinical evidence (Phase III RCTs) and superior visceral fat reduction. Sermorelin has decades of off-label clinical use, is far cheaper ($150–400/mo compounded vs. $3,000–5,000/mo for brand tesamorelin), and is more widely available. For most people outside an HIV-lipodystrophy diagnosis, sermorelin or CJC-1295/ipamorelin provides similar GH optimization at a fraction of the cost.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results

Continue Reading

← Back to Peptide Therapy

Understand your health — on your terms

Use our free tools and evidence-based guides to make smarter decisions about your metabolism, hormones, and recovery.

Take the Free Assessment →